Home
Search:
1146 feeds
357 categories
0 articles (<24 hours)
36 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

General


RSS FeedsAveXis data reinforce effectiveness of ZolgensmaŽ in treating spinal muscular atrophy (SMA) Type 1
(WorldNews Switzerland)

 
 

17 april 2019 00:05:22

 
AveXis data reinforce effectiveness of ZolgensmaŽ in treating spinal muscular atrophy (SMA) Type 1
(WorldNews Switzerland)
 


Ph 3 STR1VE data show prolonged event-free survival, early and rapid increases in CHOP-INTEND and significant milestone achievement in SMA Type 1, consistent with START trial First-in-human biodistribution datashow transduction in intended CNS targets and widespread SMN expression comparable to tissue from unaffected control More than 150 patients treated with Zolgensma, only 5% of screened patients up to 5 years old excluded due to AAV9 antibody titers greater than 1:50 Basel, April 16, 2019- AveXis, a Novartis company, today announced that interim data from its Phase 3 STR1VE trial of ZolgensmaŽ (onasemnogene abeparvovec-xioi; AVXS-101)[1] in spinal muscular atrophy (SMA) Type 1 showed...


 
14 viewsCategory: General > Europe > Switzerland
 
Annual General Meeting 2019: All motions approved
(WorldNews Switzerland)
Sulzer´s order intake grows 10% in the first quarter of 2019
(WorldNews Switzerland)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten